Sekisui Diagnostics Announces Relocation of Global Headquarters
As of June 26, 2019, Sekisui Diagnostics global headquarters has relocated to One Wall Street, Burlington, MA. One Wall Street houses 14 companies and features a fitness center and [...]
Sekisui Diagnostics Invests $1.9 million in Microbial Biopharma CDMO Business
Lexington, MA, USA – May 14, 2019 – Sekisui Diagnostics Enzyme business announces the completion of a new BioProcess Innovation Centre at the site in Maidstone, Kent by the [...]
Sekisui Diagnostics Announces the Launch of the FastPack® IP SHBG Test
The FastPack® IP SHBG is a chemiluminescent immunoassay intended for the quantitative determination of Sex Hormone Binding Globulin in human serum and plasma on the FastPack® System. Testosterone is the primary [...]
Sekisui Diagnostics PEI Expanding Again and Adding More Jobs
Sekisui Diagnostics in Charlottetown is expanding again to add capacity and jobs which will benefit Islanders and the province’s economy.
Sekisui Diagnostics PEI Named Canada’s Top 100 Employers
Sekisui Diagnostics PEI named Canada's Top 100 Employers for second year in a row.
Sekisui Diagnostics Receives FDA Clearance for SEKURE® HbA1c Assay
Lexington, MA – July 30, 2018 – Sekisui Diagnostics announces the FDA clearance of their SEKURE® HbA1c assay. The assay has been cleared to be used as an aid [...]
Sekisui Diagnostics PEI Unveils $1.2M Expansion in Charlottetown
Expansion could mean more jobs at Charlottetown plant
Sekisui Diagnostics to Receive $600,000 from PEI Province
An international bioscience company located in P.E.I. is receiving $600,000 from the province to help create more biotech jobs in P.E.I. P.E.I. Premier Wade MacLauchlan announced on Friday that [...]
Bob Schruender, CEO Joins Sekisui Medical Board of Directors
Sekisui Medical has appointed Robert Schruender to their Board of Directors in addition to current Sekisui Diagnostics group (SDG) CEO role, effective June 20th after the completion of the stockholder [...]
Sekisui Diagnostics Announces Launch of Silaris™ Influenza A&B Test
Lexington, MA – March 13, 2018 – Today Sekisui Diagnostics announces the launch of the Silaris™ Influenza A&B Test. The Silaris™ test was developed by Mesa Biotech and utilizes an affordable, [...]
Sekisui Diagnostics Announces Asset Transfer Agreement with ImmBioMed GmbH & Co. KG
March 12, 2018- Sekisui Diagnostics announced today that ImmBioMed Business Consultants GmbH & Co. KG (IBM) will acquire the specialty coagulation assets of Sekisui Diagnostics GmbH under an asset [...]